Alitera-Med-Medicinski Centar EOOD
- Address
- Krasno Selo, Bulevard Gotse Delchev 24, 1618 Sofia, Bulgaria
Alitera-Med-Medicinski Centar EOOD
Alitera-Med-Medicinski Centar EOOD is a specialized medical research facility focused on dermatological conditions, with particular expertise in chronic inflammatory skin disorders. The center is dedicated to advancing therapeutic options for patients suffering from complex dermatological diseases through rigorous clinical investigation.
- Long-term safety and efficacy studies of novel biologic therapies for inflammatory skin conditions
- Atopic Dermatitis research in both adult and adolescent populations
- Advanced immunomodulatory treatments including Nemolizumab (CD14152)
The center specializes in evaluating innovative treatments for moderate-to-severe atopic dermatitis, conducting comprehensive longitudinal studies that monitor patient outcomes over extended periods. Their research contributes to the understanding of biologic therapeutic agents and their role in managing chronic inflammatory conditions, helping to establish new standards of care for patients with challenging dermatological conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Alitera-Med-Medicinski Centar EOOD
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Long-Term Safety and Efficacy Assessment of Nemolizumab (CD14152) in Moderate-to-Severe Atopic Dermatitis Patients | Galderma S.A. | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Nemolizumab | 1 | Unknown | 2020-10-01 | 2020-10-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.